Pharmaceutical Composition Based on Two Innovative Chitosan-Containing Substances – The Chitosan-Chymopsin Complex and the Chitosan-Miramistin Complex – for Production of a Finished Dosage Form for the Treatment of Infected Wounds of Various Origins

Developed pharmaceutical composition based on two innovative chitosan-containing substances: the chitosan-chymopsin complex and the chitosan-miramistin complex, for the treatment of infected wounds in gel dosage form for external use has four types of pharmacological effects necrolytic, antimicrobial, wound healing and analgesic. The chitosan-chymopsin complex provides prolonged proteolytic action of the enzyme, restores microcirculation in wound walls, improves metabolic processes and relieves local inflammation. The chitosan-miramistin complex has a pronounced bactericidal effect against aerobic and anaerobic bacteria, gram-positive and gram-negative microorganisms, both in the form of monocultures and in the form of associations, including hospital strains with antibiotic resistance. Gel as a dosage form provides indirect anaesthetic effect due to cooling effect when applied to the damaged surface.